Modeling the relationship between cancer level in hemolymph and MarBTN in tank eDNA. by Rachael M. Giersch (22331947)

Comparison of postoperative rest and activity between APS score groups in Experiment 2. by Akihiro Ohnishi (10989900)

Survival of soft-shell clams with MarBTN compared to control clams. by Rachael M. Giersch (22331947)

“…(C) A sub-analysis of low-positive clams in which MarBTN progressed and did not regress (n = 9, dark red line), with survival starting at the time the clam was detected with >10% cancer, compared with their paired control clams starting at the same date (blue line), shows a significant decrease in time-to death. “+” marks the dates at which two negative control animals were culled before natural death (these events were censored in the survival analysis).…”

Changepoint analysis in comparison of MarBTN-specific eDNA and cancer in hemolymph. by Rachael M. Giersch (22331947)

Data from qPCR analysis of hemolymph from included clams. by Rachael M. Giersch (22331947)

Data from qPCR analysis of eDNA and matching hemolymph timepoints. by Rachael M. Giersch (22331947)

Characteristics and outcomes from clams with MarBTN and control healthy clams. by Rachael M. Giersch (22331947)

Estimated coefficients from the SARIMA model of new COVID-19 deaths assuming a gradual effect following the implementation of two ETSs and one executive order in Oregon. by Raul Cruz-Cano (3751321)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …”

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean CRT (μm ± standard deviation) significantly decreased from 504.7 ± 118.2 μm preoperatively to 302.5 ± 60.5 at 1 month, 307.5 ± 64.4 at 3 months, 286.8 ± 49.0 at 6 months, 305.3 ± 79.5 at 12 months, 288.8 ± 79.1 at 24 months, and 295.2 ± 87.4 at 36 months (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

Correlation between the amount of physical activity recorded PLUS CYCLE^® and video-observed activity. by Akihiro Ohnishi (10989900)

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …”

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…CRT in the recurrence group significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

Intraperitoneal injection protocol for inhibitors (A), inhibitors DAS and Y27632 reduced intestinal permeability (B) and intestinal adult worm burden (C) of infected mice. by Wen Wen Zheng (17721404)

S1 Fig.pdf - by Shaaista Budhani (21030221)

“…There was a trend of increased recall rates in group 2 for short-term problems, long-term problems, intervention, and incidence rates, but it did not reach statistically significant level. …”

Comparison between simulation tests and bench tests. by Yifei Li (198040)

Comparison between simulation tests and bench tests. by Yifei Li (198040)